PETALUMA, Calif., Dec. 15, 2020 /PRNewsCentre/ — RetinalGeniXTM Technologies, Inc. https://retinalgenix.com/ announced today the engagement of Amato and Partners to provide Investor Relations services. RetinalGeniXTM Technologies is a private California-based medical technology company focused on prevention of blindness through mass medical retinal screening and patient home monitoring.
RetinalGeniX is moving forward with a strategic investor relations plan that will be supported by Amato and Partners. Amato and Partners is an independent Investor Relations firm headquartered in New York City. The firm has a strong and well-recognized brand in the U.S. capital markets. The Amato team has over 40 years of experience developing and executing investor relations programs and a proven track record of achieving results both for private and public companies.
"Amato and Partners provides experienced advice and established Wall Street relationships that will cultivate company visibility with market participants including equity research analysts, investment banks and appropriate potential investors," said Jerry Katzman, M.D., RetinalGeniX’s chief executive officer. "We very much look forward to working together."
About RetinalGeniX Technologies, Inc.
RetinalGeniX Technologies, Inc. is a privately held emerging medical device company focused on preventing blindness through a cost-effective Mass Retinal Screening Device and a Patient Real-Time Home Monitoring Imaging & Physician Alert System. (A) The Mass Retinal Screening device provides retinal imaging that captures a 200° FOV without pupil dilation and detects the earliest stages of diabetic retinopathy to prevent blindness. This device requires submission to the FDA’s 510(k) approval process. (B) RetinalGeniX’s second product is RetinalCam™, the first in-home, self-monitoring device providing real-time ocular and retinal imaging and streams video to the physician. The technology enables high-risk individuals to send their physician digitized retinal images and streaming video easily from their home. This second device does not require submission to the FDA’s 510(k) approval.
Safe Harbor Statement
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the Mass Retinal Screening Device and a Patient Real-Time Home Monitoring Imaging & Physician Alert System and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon RetinalGeniX’s current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. RetinalGenix may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions. Consequently, forward-looking statements should be regarded solely as RetinalGeniX’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. RetinalGenix cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
Jerry Katzman, M.D.
Chief Executive Officer
SOURCE: RetinalGeniX Technologies, Inc.